<DOC>
	<DOCNO>NCT02205554</DOCNO>
	<brief_summary>The purpose study compare safety , pharmacokinetic property ( absorption , distribution excretion ) , analgesic activity Omnitram ( 10 mg tablet ) , Tramadol ( Ultram , 50 mg tablet ) follow oral administration 9 dos healthy subject .</brief_summary>
	<brief_title>Omnitram Pharmacokinetic Study In Healthy Volunteers</brief_title>
	<detailed_description>A Phase 1 , single-center , randomize , double-blind , placebo-controlled , three-period cross-over study compare safety , steady-state oral pharmacokinetics , clinical activity overencapsulated : 20 mg Omnitram ( 2x10 mg tablet ) , 50 mg Tramadol ( 1x50 mg Ultram tablet ) , placebo . Forty male subject normal health , 21 55 year age , randomize three parallel arm ( N=~13 ) ingest total 9 dos Omnitram , Tramadol , placebo first treatment segment ( one dose every 6 hour ) . Around 9th dose blood sample collect quantify plasma Tramadol Metabolite 1 ( M1 ) enantiomer . After 9th dose , pain tolerance assess cold pressor test ( ice cold water immersion ) . After 7th dose abuse liability measure pupil diameter assess . Subjects washout 7 day first treatment segment second treatment segment .</detailed_description>
	<mesh_term>Tramadol</mesh_term>
	<criteria>1 . Healthy male normal vital sign : systolic blood pressure &gt; 90 mm Hg &lt; 140 mm Hg ; diastolic blood pressure &gt; 50 mm Hg &lt; 90 mm Hg ; pulse 50 100 beat per minute ; respiratory rate 12 20 breathes per minute 2 . Between age 21 55 year age 3 . Able willing give inform consent 4 . Able comply study procedures 5 . Have adequate hematologic function evidence follow screen result : White Blood Cell ( WBC ) &gt; 3,500/mm3 &lt; 12,000/mm3 ; Platelet Count &gt; 150,000/mm3 &lt; 540,000/mm3 ; Hemoglobin &gt; 12.5 gm/dL &lt; 20.5 gm/dL . Have adequate liver function evidence follow screen result : Aspartate transaminase ( AST ) ≤ 60 IU/L ; Alanine transaminase ( ALT ) ≤ 83 IU ; Alkaline Phosphatase ≤ 150 IU/L ; Total Bilirubin ≤ 1.2 mg/dL ; Prothrombin Time ( PT ) &lt; 1.2 upper limit normal ( ULN ) ; Partial Thromboplastin Time ( PTT ) &lt; 1.2 ULN . 6 . Electrocardiogram ( ECG ) within normal limit determine PI 7 . Have adequate renal function evidence follow screen result : Glomerular filtration rate ( GFR ) calculate CockcroftGault formula &gt; 60 ml/min . Urinalysis demonstrate &lt; +1 glucose , +1 ketone , +1 protein 8 . Negative urine test substance abuse , include opiate , per clinical research unit ( CRU ) standard 9 . Negative serology test HIV , hepatitis B surface antigen hepatitis C virus antibody 10 . Body Mass Index ( BMI ) 19.0 32 kg/m 11 . Cold pressor screen result follow : 1 ) pain tolerance &gt; 20 second &lt; 120 second 1 . Oral temperature &gt; 38°C history current illness 2 . History seizure , epilepsy , recognize increase risk seizure ( e.g. , head trauma , metabolic disorder , alcohol drug withdrawal ) 3 . History cirrhosis laboratory evidence liver disease 4 . Use alcohol within 24 hour day 1 end study ; grapefruit , grapefruitrelated citrus fruit ( e.g. , Seville oranges , pomelo ) , grapefruit juice grapefruitrelated juice , medication , within 7 day study drug administration end study 5 . History previous anaphylaxis , severe allergic reaction Tramadol , codeine , opioid drug 6 . Use monoamine oxidase ( MAO ) inhibitor ( include linezolid ) , Serotonin Reuptake Inhibitors , SerotoninNorepinephrine Reuptake Inhibitors , prescription overthe counter ( OTC ) medication know induce inhibit drug metabolism , include cytochrome P450 2D6 ( CYP2D6 ) , drug may affect serotonergic neurotransmitter system include , limited , triptans , dextromethorphan , tricyclic antidepressant , bupropion , lithium , tramadol , dietary supplement tryptophan St. John 's Wort , antipsychotic dopamine antagonist . These restriction maintain 14 day study day 1 , subject completes study 7 . Any unstable acute chronic disease could interfere evaluation safety study drug determine principal Investigator dialogue Sponsor Medical Monitor 8 . Unlikely comply study protocol 9 . Known suspected alcohol drug abuse within past 6 month 10 . Received another investigational agent within 4 week Day 0 , within five halflives Day 0 , whichever longer ; receive investigational agent study 11 . Any concurrent disease condition opinion investigator impair subject 's ability complete trial . Psychological , familial , sociological , geographical medical condition , Investigator 's opinion , could compromise compliance objective procedure protocol , obscure interpretation trial data</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Analgesia</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Treatment</keyword>
</DOC>